THE GRADUATE INSTITUTE GENEVA

GLOBAL HEALTH CENTRE

Webinar

Regulating Drug Prices: National and Global Implications of Canada's Recent Reforms

Elena Lungu

17 December 2019

Q&A Session with the Participants

15:59:33
From Sadia Kaenzig to All panelists : Hello, thanks for organizing this. Im in and can hear you

16:08:05
From Roger Paul Kamugasha to All panelists : Hi, this is Roger Paul of The Health Times Global Limited and Member of the WHO Global Civil Society Task Force on TB and also the new Community Representative to the TB Alliance Stakeholders Association.

16:08:48
From Global Health Centre Research, Graduate Institute Geneva : please type messages to All panelists and attendees

16:15:20
From Roger Paul Kamugasha to All panelists : Am based in Kampala, Uganda

16:19:07
From Marcela Vieira to Roger Paul Kamugasha and all panelists : Hello Roger Paul, welcome to our webinar and thanks for joining.

16:22:12
From Tolulope Osigbesan to All panelists : Can you share ex of countries prices in Canada will be benchmarked with please?

16:22:56
From Tolulope Osigbesan to All panelists : Now seen, thanks

16:24:37
From Marcela Vieira : Everyone, please make sure you select the option to "all panelists and attendees" when you send your comments and questions in the chat. Thank you.

16:25:59
From Ines Hassan : Hello. Will we be able to get a copy of these slides after the presentation? Thank you. Ines Hassan

16:27:09
From Marcela Vieira : Hello Ines, yes, the slides are going to available online along the recording of the webinar at the Knowledge Portal for Innovation and Access to Medicines at www.knowledgeportalia.org

16:27:28
From Ines Hassan : Thank you Marcela

16:29:42
From Diego Junqueira Torres da Silva : Hi. Just to confirm an information, compulsory licensing is not allowed in Canada?

16:31:56
From Sergiy Kondratyuk : Why MRP is non transparent?

16:41:14
From Marcela Vieira : Dear Elena, thank you for your presentation. You mentioned that currently the PMPRB Board can decide that a medicine is excessively priced and ask the patentee either to reduce the price or to pay back excess revenues. Could you please provide more information about how the Board determines when a price is excessive and if there has been concretes cases in which this has happened. And if there has been any changes regarding this in the new regulation. Thank you.

16:44:25
From Eli Gerber to All panelists : Hi Elena - in the absence of compulsory licensing, is there a backstop to ensure that drug manufacturers can't withdraw entirely from the Canadian market?

16:50:30
From Reinhard Huss : Why do you not assess at source and ask pharmaceutical companies to justify their pharmaceutical prices because of transparent and verifialble research expenditure on a new medicine. This approach would correspond with the concept of social responsibility and accountability of companies.

16:52:41
From Krisantha Weerasuriya : A comment - Canada welcome to being a member of DrugPrice Land of the Low and Middle income countries. When we try to negotiate prices all we are offered is list prices and not the actual negotiated prices. Ironic that Low and Middle Income countries pay the highest prices!

16:53:32
From Anna Apostolakis : What should patentees report on July 1st 2020 for the Jan2020 to June2020 data filing? PMPRB7 or PMPRB11

16:57:55
From Reinhard Huss : Should a patentee not be obliged to report the verifiable R&D costs of a medicine in return for a patent granted by the patent office of the state?

17:00:46
From Krisantha Weerasuriya : What has been described is an extremely complex system which is beyond the capabilities of Low and Middle Income countries. There is a proposal that would make prices proportionate to the GDP ?

17:01:02
From Eli Gerber to All panelists : Thank you both!

17:01:12
From Ines Hassan : Thanks all

17:01:14
From Sergiy Kondratyuk : Thank you very much for the webinar!